FDA Approves Oxbryta, the First Medicine Specifically Targeting The Root Cause of Sickle Cell Disease

U.S. Food and Drug Administration approved Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.
Source: Healthline

Read More